Marion Webb has been writing about medtech since 2017, specializing in covering buzzy segments such as robotic surgery, digital therapeutics and femtech with in-depth features and interviews with leading experts. Her role includes reporting live from industry events, moderating panel discussions and podcasts, tweeting breaking news and engaging KOLs to provide high-quality, business-critical content for Medtech Insight. Marion has been writing about health care issues for more than two decades. She was a long-time biotech reporter at the San Diego Business Journal, worked at Bloomberg News, and contributed to the Los Angeles County Medical Association’s Physician Magazine. Marion was born and raised in Germany, is fluent in German and conversational in Spanish. Off the job, she’s a competitive runner, avid cyclist and swimmer, and enjoys spending time with her domestic partner and her German Shorthair Pointer mix Cora.
Latest from Marion Webb
Women’s health start-up Midi Health has raised $100m in a Series D financing, led by Goodwater Capital with new investors Foresite Capital and Serena Ventures. Midi, which focuses on women in midlife, said the money will support the next phase of growth.
Medtronic has agreed to acquire Cathworks for up to $585m, converting a long-standing partnership into full ownership as it expands its footprint in coronary physiology and AI-enabled cardiovascular tools.
INBRAIN unveiled a bidirectional "rice-sized" BCI chip partnership, Merck commercialization progress and new speech-decoding trial in France as it advances its graphene-based cortical interface toward commercialization, pending regulatory clearance.
Medtech Insight was invited to moderate a panel discussion with leading experts in neuroscience and AI during INBRAIN’s five-year anniversary in Barcelona, Spain. Panelists discussed the promises, perils in BCI development, neuroethics and outlook.
In this final part of a three-part series, Medtech Insight spoke with a neuroethicist and the first person in a trial using a BCI implant for stimulating hand movement. This story explores ethical considerations that arise when projects can no longer support patients with implanted devices.
BioStem Technologies’ buyout of BioTissue Holding’s surgical and wound-care business adds cryopreserved and sterile technologies, Cryotek and SteriTek, and a direct sales force focused on acute care settings.